Diagnostik und Therapie von Chlamydia-trachomatis-Infektionen

Meyer, Thomas

doi:10.1007/s00105-011-2194-x

Cited by 4 publications

(5 citation statements)

References 26 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… The most important reason for treatment failure is inadequate medicine or dosage and insufficient treatment course, which all tend to induce the drug resistance and persistent infection. Therefore, appropriate education, standard, and enough-course therapy[ 8 33 34 35 ] should be given to diagnosed patients (medium quality of evidence, strong recommendation) We can change the medicines[ 4 ] or prolong the therapy course[ 4 5 34 35 36 37 ] for those therapy-resistant patients. For example, we can use doxycycline or clarithromycin for 14 to 21 days.…”

Section: Linical a Dvice For mentioning

confidence: 99%

Section: Linical a Dvice For mentioning

confidence: 99%

“…We can change the medicines[ 4 ] or prolong the therapy course[ 4 5 34 35 36 37 ] for those therapy-resistant patients. For example, we can use doxycycline or clarithromycin for 14 to 21 days.…”

Section: Linical a Dvice For mentioning

confidence: 99%

See 2 more Smart Citations

Consensus by Chinese Expert Panel on Chlamydia trachomatis-Resistant and Chlamydia trachomatis-Persistent Infection

Guo²,

Wang

et al. 2017

Chinese Medical Journal

View full text Add to dashboard Cite

Section: Linical a Dvice For mentioning

confidence: 99%

Section: Linical a Dvice For mentioning

confidence: 99%

See 1 more Smart Citation

Consensus by Chinese Expert Panel on Chlamydia trachomatis-Resistant and Chlamydia trachomatis-Persistent Infection

Guo²,

Wang

et al. 2017

Chinese Medical Journal

View full text Add to dashboard Cite

“…Unfortunately, in some countries azithromycin is not permitted to be administered in pregnancy, and therefore erythromycin or amoxicillin is regarded as an option. 269,272 In countries, where josamycin is available, it is regarded as an alternative drug with a well-tolerated regimen. 243 In the first trimester, it is only recommended under strict conditions.…”

Section: Management Of Patientsmentioning

confidence: 99%

Background review for the ‘2015 European guideline on the management ofChlamydia trachomatisinfections’

et al. 2015

View full text Add to dashboard Cite

SummaryChlamydia trachomatis infections are major public health concerns globally. Of particular grave concern is that the majority of persons with anogenital Chlamydia trachomatis infections are asymptomatic and accordingly not aware of their infection, and this silent infection can subsequently result in severe reproductive tract complications and sequelae. The current review paper provides all background, evidence base and discussions for the 2015 European guideline on the management of Chlamydia trachomatis infections (Lanjouw E, et al. Int J STD AIDS 2015). Comprehensive information and recommendations are included regarding the diagnosis, treatment and prevention of anogenital, pharyngeal and conjunctival Chlamydia trachomatis infections in European countries. However, Chlamydia trachomatis also causes the eye infection trachoma, which is not a sexually transmitted infection. The 2015 European Chlamydia trachomatis guideline provides up-to-date guidance regarding broader indications for testing and treatment of Chlamydia trachomatis infections; clearer recommendation of using validated nucleic acid amplification tests only for diagnosis; advice on (repeated) Chlamydia trachomatis testing; recommendation of increased testing to reduce the incidence of pelvic inflammatory disease and prevent exposure to infection and recommendations to identify, verify and report Chlamydia trachomatis variants. Improvement of access to testing, test performance, diagnostics, antimicrobial treatment and follow-up of Chlamydia trachomatis patients are crucial to control its spread.

show abstract

“…Many of them are designed as duplex assays analysing both pathogens. 18 The recently developed PelvoCheck CT/NG test kit from Greiner-Bio-One GmbH also simultaneously analyses CT and NG and can be used for both urine and swabs. To evaluate the performance of the PelvoCheck CT/NG test in FVU, we examined urine samples obtained during Chlamydia screening by both PelvoCheck CT/NG and Roche COBAS TaqMan CT Test V.2.0 as a comparative NAAT, as well as FVU specimens pretested for NG in another laboratory by PelvoCheck CT/NG and an in-house PCR test based on porA gene sequences.…”

Section: Introductionmentioning

confidence: 99%

Performance evaluation of the PelvoCheck CT/NG test kit for the detection ofChlamydia trachomatisandNeisseria gonorrhoeae

Meyer

Klos

Kofler³

et al. 2016

BMJ Open

View full text Add to dashboard Cite

ObjectiveAssessment of the performance of the PelvoCheck CT/NG test (Greiner-Bio-One GmbH) to detect Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) in first-void urine (FVU) of females.DesignA cross-sectional study to compare the PelvoCheck CT/NG with COBAS TaqMan CT Test V.2.0 (Roche) for the detection of CT and with an in-house porA-based PCR for the detection of NG in FVU specimens. In addition, pools of 5 FVU specimens containing only CT-negative or 1 CT-positive and 4 CT-negative samples were tested. Abbott RealTime CT/NG was used as an additional test to resolve discordant results.SettingSamples sent from six laboratories were tested at the University Medical Center Hamburg.ParticipantsUrine samples were from 1622 female patients attending gynaecological practices for chlamydia screening, another 120 urine samples were from patients pretested for NG at Synlab, Medical Service Center, Weiden GmbH. In addition, 50 urine samples spiked with various concentrations of reference material were used.ResultsFor the detection of CT and NG, the sensitivity and specificity of the PelvoCheck CT/NG test were 98.8% and 100%, and 98.3% and 98.2%, respectively. The data obtained with the PelvoCheck CT/NG for pooled urine specimens resulted in a positive agreement of 90.9% and a negative agreement of 100%.ConclusionsThe PelvoCheck CT/NG assay is a suitable test method for the detection of CT and NG in female FVU samples, with sensitivity and specificity comparable with other Food and Drug Administration approved CT/NG nucleic acid amplification tests. To the best of our knowledge, this is the first commercial test system validated for the analysis of pooled urine specimens. No false-positive or invalid result was observed in 55 analysed pools. Nevertheless, 5 samples were false negative due to a target concentration below the limit of detection of the PelvoCheck CT/NG test as a consequence of pooling-associated dilution.

show abstract

Diagnostik und Therapie von Chlamydia-trachomatis-Infektionen

Cited by 4 publications

References 26 publications

Consensus by Chinese Expert Panel on Chlamydia trachomatis-Resistant and Chlamydia trachomatis-Persistent Infection

Consensus by Chinese Expert Panel on Chlamydia trachomatis-Resistant and Chlamydia trachomatis-Persistent Infection

Background review for the ‘2015 European guideline on the management ofChlamydia trachomatisinfections’

Performance evaluation of the PelvoCheck CT/NG test kit for the detection ofChlamydia trachomatisandNeisseria gonorrhoeae

Contact Info

Product

Resources

About